OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	810
Antibody treatment to deplete transthyretin amyloid deposits in the heart	521
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	363
Intravascular imaging improves outcomes	345
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	324
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	312
Travelling with heart failure: risk assessment and practical recommendations	312
Takotsubo syndrome: pathophysiological insights and innovations in patient care	309
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	304
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	304
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	252
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	248
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	246
Genetics and mechanisms of thoracic aortic disease	241
Alternative defibrillation strategies improve outcomes	239
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	237
Detection of subclinical hypertrophic cardiomyopathy	234
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	222
Electron microscopy of cardiac 3D nanodynamics: form, function, future	214
Defining iron deficiency in patients with heart failure	212
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	211
Think Aorta: aortic dissection awareness and perspectives from the patient	207
Hallmarks of cardiovascular ageing	204
Neuromodulation reduces inflammation in HFpEF	193
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	187

CSDE1 regulates LDL receptor levels	182
Preparticipation screening reduces SCD in young athletes	176
LDL-cholesterol lowering with obicetrapib	173
Increased degradation of desmosomal proteins in ACM	172
No benefit of apoA-I infusion after myocardial infarction	172
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	170
Catheter ablation improves outcomes in patients with AF and end-stage HF	168
Tailored therapeutics for cardiomyopathies	165
Colchicine in acute coronary syndromes: the present and the possible future	158
Decongestion in heart failure: medical and device therapies	157
Prevention of atherosclerosis from childhood	138
Targeting immune cell recruitment in atherosclerosis	126
Extracellular matrix in vascular homeostasis and disease	125
The oral microbiome in the pathophysiology of cardiovascular disease	124
Reactive oxygen species in hypertension	121
Graded exercise therapy should not be recommended for patients with post-exertional malaise	118
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	116
Donor macrophages influence rejection of transplanted hearts	114
Modelling pre-eclampsia and its cardiovascular effects	107
RNA interference lowers triglyceride levels	105
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	105
Cardiac sarcomere turnover by unidirectional replacement of proteins	104
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	103
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	101
Evidence does not support the reduction of added sugar intake from all food sources	97
Promising novel siRNA for the treatment of hypertension	96
Semaglutide is beneficial in patients with HFpEF and obesity	94
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	93
Global epidemiology of heart failure	92
An epigenome editing approach induces durable silencing of Pcsk9	89
BP management with a village-doctor-led strategy	86
Single-cell profiles of CHD and CM	86
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	85
Development of a miniature, bioresorbable, light-activated pacemaker	84
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	84
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	84
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	82
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	80
The role of the molecular autopsy in sudden cardiac death in young individuals	80
Heart transplantation: advances in expanding the donor pool and xenotransplantation	78
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	78
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	77
CNR1 antagonism attenuates cannabis-induced atherosclerosis	76
Efferocytosis in atherosclerosis	76
New insights into dietary cholesterol absorption	75
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	75
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	75
Gut bacteria can break down cholesterol	70
Cardiovascular benefits of fermented foods and beverages: still up for debate	70
Baxdrostat beneficial in uncontrolled or resistant hypertension	65

Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	65
Gene–environment interactions in the pathogenesis of cardiovascular disease	64
Improving medication adherence in cardiovascular disease	63
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	62
PCSK9 inhibition for primary prevention of cardiovascular events	62
Renal denervation for hypertension	62
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	62
Mechanisms and treatment of pulmonary arterial hypertension	60
Cardiovascular disease and cancer: shared risk factors and mechanisms	59
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	57
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	56
Cardiac optogenetics: controlling the heart with light	55
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	55
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	54
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	51
Heart failure and obesity: novel insights leading to new treatment paradigms	50
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	48
Integration of cardiovascular and mental health: from concepts to the clinic	45
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	42
Epigenetic editing in cardiovascular medicine: moving beyond the hype	42
The need for increased pragmatism in cardiovascular clinical trials	42
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	41
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	41
Blood pressure and its variability: classic and novel measurement techniques	41
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	41
The cardiac parasympathetic system has two parallel circuits	40
Black In Cardio: promoting diversity and representation in the cardiovascular field	39
Inhibiting aldosterone synthase reduces blood pressure	39
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	38
Age-induced senescence impairs the neurovascular interface in the heart	34
Gout flares can precede cardiovascular events	33
ASGR1 inhibition stimulates cholesterol excretion	32
Colchicine in patients with cardiovascular disease	32
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	31
Sotatercept as add-on therapy for advanced PAH	30
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	30
Consequences of ionizing radiation exposure to the cardiovascular system	26
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	26
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	26
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	26
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	24
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	24
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	23
Genome editing prevents hypertrophic cardiomyopathy in mice	23
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	23
Surgery safer than endovascular therapy for CLTI	23
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	22
Preserving the future of heart transplantation	22
Characterization of the F8 gene: a silver lining in a dark cloud	22
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	22
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	21
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	21
Building the Australian Cardiovascular disease Data Commons	21
A role for lipophagy in atherosclerosis	20
High troponin I levels predict death after surgery	20
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	20
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	20
Charting the future of cardiology with large language model artificial intelligence	19
Alain Cribier (1945–2024)	19
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	19
The dynamic cardiac cellular landscape: visualization by molecular imaging	19
Sustained BP reduction with renal denervation	19
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group	17
Mind the gap: sex-related differences in cardiovascular disease	17
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	16
Unravelling the genetic heart–brain connection using MRI	16
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	16
Cardiac splicing as a diagnostic and therapeutic target	15
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	15
The ongoing quest for the first total artificial heart as destination therapy	14
Current concepts and novel targets for antiplatelet therapy	14
Contemporary pharmacological treatment and management of heart failure	14
Epidemiology and prevention of venous thromboembolism	14
Single-cell transcriptomics for the assessment of cardiac disease	14
The microtubule cytoskeleton in cardiac mechanics and heart failure	14
Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine	14
Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation	14
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	14